Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces...

Full description

Bibliographic Details
Published in:Frontiers in Medicine
Main Authors: Diego Luigi Cortinovis, Francesca Colonese, Maria Ida Abbate, Luca Sala, Marco Meazza Prina, Nicoletta Cordani, Elisa Sala, Stefania Canova
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Subjects:
DLL3
small-cell lung cancer
rovalpituzumab tesirine
tarlatamab
molecular classification
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.989405/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.989405/full

Similar Items